IASO Bio's Ixazomib Injection Receives 'China First-in-Class' Honor, Highlighting China's Biopharmaceutical Innovation
IASO Biotechnology
Cancer Treatment New Drug Developer
On June 28, 2024, at the "2024 Inaugural Chinese Biopharmaceutical Association CBA-China Annual Conference in China" held at the Suzhou International Expo Center, IASO Bio's Icarus Injection was awarded for its excellent innovation and therapeutic effects.Chinese Company's First-in-Class Target Drug "China First-in-class" Honor, Becoming the Only Brand in the Cell Therapy Category to Receive This Recognition。
This honor is not only a high recognition of IASO Bio's innovative capabilities and R&D strength in the biopharmaceutical field, but also an affirmation of the innovation capabilities of China's biopharmaceutical industry.
In the past few years, China's innovation capability in the biopharmaceutical field has significantly improved. From 2015 to 2021, there were few "first-in-class" drugs on the market, and most of them were foreign products. However, from 2021 to 2023, data on the approval of new drugs in China shows that among 35 Chinese "first-in-class" drugs, the proportion of locally produced ones has notably increased, accounting for nearly half, including four self-developed varieties. Chinese innovative drugs have not only achieved "China First-in-Class," but some products are even leading globally.
IASO Bio's Idecabtagene Vicleucel Injection Receives Esteemed Recognition, Demonstrating the Innovative Strength of China's Biopharmaceutical Industry. We look forward to further advancing biopharmaceutical technology in China and globally through broader international platforms, making greater contributions to the health of humanity worldwide.
About IASO Bio
